Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc > I am a champion...

<< Previous

Bullboard Posts

Next >>

Comment by SPCEO1on Mar 30, 2023 1:31pm

64 Views

Post# 35369692

RE:RE:I am a champion...

I am not sure I understand your concern about paying off the convert. They have the money forthat committed from Marathon. Do you see some way Marathon can back out of that commitment that you are concerned about?

palinc2000 wrote:
I understand your frustration but I cant see what positive news or events or anything they can say.
We already know that Q-1 revenues are in line with achieving the Yearly guidance for 2023....Unless there is a drastic overdelivery in the sales I dont think re affirming guidance would move the needle
With regards to TH 1902 we will know soon but What can they say until final determination
We know their position in Nash which is a pause until they find a partner ....They surely wont disclose anything until they have finalised an agreement

I am crossing my fingers that they have the necessary funds to pay the balance of the damn Convert in June ..... Cash is the big problem ....and survival is the focus for now....Cant change that situation with hype!!!!

A partner in Nash with a substantial down payments would change things overnight
1902??? Dont know what to expect

scarlet1967 wrote:
They are well engaged with HIV communities which is great as for investors we saw an example of how/when they should be informed from Akero's PR. Starting with logos they go on talking about "positive" meeting with FDA, anticipated "details" of their trial....
Note the talks with FDA are still ongoing yet Akero decided to inform the market about it's progress!
As for THTX to my knowledge they never announced NDA's for NASH or oncology, approvals of applications in timely manner instead they decided to bundle up the "good" news and release them some 3 or more months later. Two different strategies one with current and more frequent updates the other one with longer spans of time between updates. As an investor I personally absolutely prefer the former approach, too many unknowns unnecessarily stop any new investors from getting involved therefore Akero and the likes feed the market with as much current information as they can which is the only right way of getting investors educated/excited and hopeful. I did send an email to IR today asking them once again to change their communication strategies as I find it extremely hard to understand why they keep using the same failed communication strategy.

https://www.fiercepharma.com/marketing/theratechnologies-champions-showcases-thriving-minority-individuals-living-hiv